The non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes, and it was demonstrated that their long-term use may decrease the risk of colorectal, esophageal, breast, lung, prostate, liver, skin, and cervical cancers [173], which is in accordance to the previously discussed oncogenic role of inflammation. This evidence concerns the gene PTGS2 and cervical cancer.